AstraZeneca stock falls after FDA panel votes against new cancer drug
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
